Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Prognosis of patients undergoing salvage allogeneic stem cell transplantation for refractory
leukemia or other refractory myeloid malignanies is poor. One of the approaches to augment
graft-versus-leukemia effect the use of post-transplantation bendamustine in
graft-versus-host disease prophylaxis. Despite high frequency of responses and durable
remissions after this approach majority of patients develop a serious complication - cytokine
release syndrome, which can be life-threatening in some patients. On the other hand
post-transplantation cyclophocphamide was reported to abort cytokine release syndrome that
sometimes occurs after graft transfusion in patients after haploidentical graft transfusion.
The aim of this study is to evaluate if the combination of post-transplantation bendamustine
(PTB) and post-transplantation cyclophosphamide (PTCY) facilitates comparable graft-versus
leukemia effect to PTB, but with better safety profile and reduced incidence of severe
cytokine release syndrome.